Clinical Trial Update: Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 [NA]

View source ↗

Summary

The study completed and evaluated whether sorafenib affects the uptake of radiolabeled bevacizumab or girentuximab (cG250) in clear cell renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Nexavar (Sorafenib)
• girentuximab (cG250) (girentuximab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Clear Cell Renal Cell Carcinoma | NA | Status: COMPLETED